62P Updated overall survival and safety with ripretinib vs sunitinib in patients with advanced gastrointestinal stromal tumor previously treated with imatinib and harboring KIT exon 11 + 17/18 mutations: ctDNA analysis from INTRIGUE

J-Y. Blay, R.L. Jones, H. Gelderblom, S. George, P. Schöffski,M. von Mehren, J.R. Zalcberg,Y-K. Kang, A.R. Abdul Razak, J.C. Trent, S. Attia,A. Le Cesne, E. Davis, K. Sprott, P. Cox, M.L. Sherman, R. Ruiz-Soto, M. Heinrich, S. Bauer

ESMO Open（2024）

引用 0|浏览1